Remi Droller - Orphazyme Director
| ORPHA Stock | DKK 1,075 19.60 1.79% |
Director
Mr. Remi Droller serves as Director of Orphazyme AS. He is Managing Partner of Kurma Partners. He has MS in molecular biology and MS in finance and Innovation Management . Remi joined Kurma in September 2010. He was previously with CDC Innovation from 2000 to 2003 and with AGF Private Equity from 2003 to 2010 where he was in charge of the development of the Life Sciences investment activities. During this period, Remi served on the board of several investee companies such as Adocia, Bioalliance Pharma, Domain Therapeutics, Integragen, Novagali Pharma, Prosensa and Zeland Pharma.
| Age | 39 |
| Phone | 45 39 17 82 72 |
| Web | https://www.orphazyme.com |
Orphazyme Management Efficiency
The company has return on total asset (ROA) of (1.334) % which means that it has lost $1.334 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (4.8658) %, meaning that it generated substantial loss on money invested by shareholders. Orphazyme's management efficiency ratios could be used to measure how well Orphazyme manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 8 records | DIRECTOR Age | ||
| Claus Braestrup | Bavarian Nordic | 72 | |
| Peter Kurstein | Bavarian Nordic | 59 | |
| Petra Pielken | Bavarian Nordic | N/A | |
| Erik Hansen | Bavarian Nordic | 66 | |
| Anne Eberhard | Bavarian Nordic | 55 | |
| Frank Verwiel | Bavarian Nordic | 56 | |
| Elizabeth Anderson | Bavarian Nordic | 61 | |
| Peter KursteinJensen | Bavarian Nordic | 62 | |
Management Performance
| Return On Equity | -4.87 | |||
| Return On Asset | -1.33 |
Orphazyme AS Leadership Team
Elected by the shareholders, the Orphazyme's board of directors comprises two types of representatives: Orphazyme inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Orphazyme. The board's role is to monitor Orphazyme's management team and ensure that shareholders' interests are well served. Orphazyme's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Orphazyme's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Remi Droller, Director | ||
| Anders Hinsby, CEO | ||
| Anders Hedegaard, Director | ||
| MBA MSc, CFO CEO | ||
| Georges Gemayel, Chairman of the Board | ||
| Jennifer McCann, I US | ||
| Bo Hansen, Deputy Chairman of the Board | ||
| Anders Vadsholt, Interim Chief Executive Officer, Chief Financial Officer | ||
| Thomas Blaettler, Chief Medical Officer | ||
| Catherine Moukheibir, Director | ||
| Sten Verland, Director | ||
| Kim Stratton, Chief Executive Officer | ||
| Martin Bonde, Director | ||
| Thomas Jensen, Chief Scientific Officer | ||
| Martijn Kleijwegt, Director |
Orphazyme Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Orphazyme a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -4.87 | |||
| Return On Asset | -1.33 | |||
| Profit Margin | (2.76) % | |||
| Operating Margin | (15.38) % | |||
| Current Valuation | (12.81 M) | |||
| Shares Outstanding | 35.31 M | |||
| Shares Owned By Insiders | 1.36 % | |||
| Shares Owned By Institutions | 8.13 % | |||
| Price To Book | 0.47 X | |||
| Price To Sales | 1.05 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Orphazyme in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Orphazyme's short interest history, or implied volatility extrapolated from Orphazyme options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Orphazyme AS. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation. Note that the Orphazyme AS information on this page should be used as a complementary analysis to other Orphazyme's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Money Flow Index module to determine momentum by analyzing Money Flow Index and other technical indicators.
Complementary Tools for Orphazyme Stock analysis
When running Orphazyme's price analysis, check to measure Orphazyme's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Orphazyme is operating at the current time. Most of Orphazyme's value examination focuses on studying past and present price action to predict the probability of Orphazyme's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Orphazyme's price. Additionally, you may evaluate how the addition of Orphazyme to your portfolios can decrease your overall portfolio volatility.
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Stocks Directory Find actively traded stocks across global markets | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data |